On Nov 07, major Wall Street analysts update their ratings for $Apellis Pharmaceuticals (APLS.US)$, with price targets ranging from $30 to $55.
Goldman Sachs analyst Salveen Richter maintains with a buy rating, and adjusts the target price from $74 to $36.
Mizuho Securities analyst Graig Suvannavejh maintains with a hold rating.
Baird analyst Colleen M. Kusy maintains with a buy rating, and adjusts the target price from $92 to $55.
Oppenheimer analyst Francois Brisebois maintains with a buy rating, and adjusts the target price from $65 to $40.
Piper Sandler analyst Biren Amin maintains with a hold rating, and adjusts the target price from $40 to $32.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
The assessment post the Q3 report indicates that there's potential for a reevaluation of the stock in 2024, presenting an opportunity to build a new investment thesis following the 'post-GA' period. This is based on the high conviction in the prospects of C3G and IC-MPGN, where the data appear exceptionally robust and seem to surpass that of the oral competitor, even in a wider context.
The company's recent Syfovre revenues were below anticipated levels. Analysts are seeking further understanding regarding the geographic atrophy market but believe that the present valuation might not fully recognize the market's potential. Additionally, the prospective introduction in C3G/IC-MPGN may compensate for the more gradual growth in the GA segment.
The company reported results for Q3 2024, which featured a decline in Syfovre revenue on a sequential basis due to modest growth in vial numbers coupled with a reduced net price and heightened competition.
The company reported a Q3 topline of $196.8M, which fell short of both the anticipated figure of $202.2M and the Street's estimate of $201M. This shortfall was attributed to higher G/N adjustments and a lower number of Syfovre vials compared to expectations.
The firm believes that the third quarter has validated the perspective of a decelerating geographic atrophy market, suggesting a need for adjustments in Syfovre forecasts. The expectation of progressively negative remarks on pricing and a more tempered ascent to peak levels is anticipated to continue impacting the stock's performance. The firm advises investors against initiating a position in the shares at this point.
Here are the latest investment ratings and price targets for $Apellis Pharmaceuticals (APLS.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$Apellis Pharmaceuticals (APLS.US)$的評級，目標價介於30美元至55美元。
高盛集團分析師Salveen Richter維持買入評級，並將目標價從74美元下調至36美元。
瑞穗證券分析師Graig Suvannavejh維持持有評級。
貝雅分析師Colleen M. Kusy維持買入評級，並將目標價從92美元下調至55美元。
奧本海默控股分析師Francois Brisebois維持買入評級，並將目標價從65美元下調至40美元。
派傑投資分析師Biren Amin維持持有評級，並將目標價從40美元下調至32美元。
此外，綜合報道，$Apellis Pharmaceuticals (APLS.US)$近期主要分析師觀點如下：
評估發佈Q3報告表明，2024年股票可能重新評估的潛力，爲在『後GA』期間制定新的投資理念提供了機會。這是基於對C3G和IC-MPGN前景高度確信，其中的數據表現異常穩健，似乎超越了口服競爭對手，即使在更廣泛的背景下。
公司最近的Syfovre營業收入低於預期水平。分析師正在尋求進一步了解地理性萎縮市場，但他們相信目前的估值可能還沒有充分認識到市場的潛力。此外，C3G/IC-MPGN的潛在推出可能會彌補地理性萎縮市場段的更漸近增長。
公司公佈了2024年Q3的業績，其中Syfovre營業收入出現了順序基礎上的下降，這是由於小瓶數量的適度增長，加上淨價格降低和競爭加劇。
公司報告了19680萬的Q3營業收入，未能達到預期的20220萬和街道估計的20100萬。這一差距歸因於較高的G/N調整和Syfovre小瓶數量低於預期。
公司認爲第三季度已驗證了地理性萎縮市場減速的觀點，暗示需要調整Syfovre預測。對定價傳遞逐漸負面評論的預期以及到達峯值水平的更溫和上升將繼續影響股票的表現。公司建議投資者目前不要介入股票。
以下爲今日6位分析師對$Apellis Pharmaceuticals (APLS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
